CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.

Allogeneic hematopoietic stem cell transplantation can induce considerable tumor remissions in metastatic renal-cell carcinoma (RCC) patients. The precise effector mechanisms mediating these graft-versus-tumor reactions are unknown. We studied RCC-directed CD8(+) T-cell responses in blood lymphocytes of healthy individuals matched with established RCC cell lines for HLA-class I. In 21 of 22 allogeneic mixed lymphocyte/tumor-cell cultures (MLTCs), RCC-reactive cytotoxic T-lymphocytes (CTLs) were readily obtained. From MLTCs, 121 CD8(+) CTL clones with memory phenotype were isolated. Their anti-RCC reactivity was restricted by multiple classical HLA-Ia molecules, in particular by HLA-A2, -A3, -B7, -B44, -Cw7, and by a nonclassical HLA-Ib determinant. Extensive cross-reactivity analyses on a broad target panel identified CTLs that recognize antigens with expression restricted to renal tissue or to renal and colon tumors. Other CTLs were directed against antigens with broader tissue distribution being expressed in various epithelial and nonepithelial tumors or, additionally, in hematopoietic cells. With microcapillary liquid chromatography and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF)/TOF mass spectrometry, we identified the HLA-A*0301-associated nonpolymorphic peptide KLPNSVLGR encoded by the ubiquitously expressed Eps15 homology domain-containing 2 gene as a CTL target. Defining human RCC antigens recognized by alloreactive CTLs may allow to improve the specificity and efficiency of allogeneic cell therapy (eg, specific donor-lymphocyte infusions or vaccination) in metastatic RCC patients.

[1]  T. Zimmerman,et al.  Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-γ-producing T cells , 2004, Bone Marrow Transplantation.

[2]  G. Hortobagyi,et al.  Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. , 2003, Blood.

[3]  P. Pisa,et al.  Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma , 2003, Bone Marrow Transplantation.

[4]  Hans-Georg Rammensee,et al.  Integrated functional genomics approach for the design of patient-individual antitumor vaccines. , 2002, Cancer research.

[5]  C. Voena,et al.  Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. , 2002, Blood.

[6]  O. Tsitsilonis,et al.  HER‐2/neu–derived peptide epitopes are also recognized by cytotoxic CD3+CD56+ (natural killer T) lymphocytes , 2002, International journal of cancer.

[7]  T. Zimmerman,et al.  Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Moyad,et al.  Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? , 2002, Urology.

[9]  S. Confalonieri,et al.  The Eps15 homology (EH) domain , 2002, FEBS letters.

[10]  A. Novick,et al.  Mechanisms of immune evasion by renal cell carcinoma: tumor-induced T-lymphocyte apoptosis and NFkappaB suppression. , 2002, Urology.

[11]  T. Wölfel,et al.  The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. , 2002, Journal of immunological methods.

[12]  S. Anfossi,et al.  The analysis of the natural killer‐like activity of human cytolytic T lymphocytes revealed HLA‐E as a novel target for TCR α/β‐mediated recognition , 2001 .

[13]  C. Hillyer.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation , 2001 .

[14]  S. Anfossi,et al.  The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR alpha/beta-mediated recognition. , 2001, European journal of immunology.

[15]  G. Willimsky,et al.  Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse , 2000, Gene Therapy.

[16]  W. Linehan,et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. , 2000, The New England journal of medicine.

[17]  H. Zarour,et al.  Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. , 2000, Blood.

[18]  R. Fisher,et al.  Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. , 2000, The cancer journal from Scientific American.

[19]  D. Louis,et al.  EHD2, EHD3, and EHD4 encode novel members of a highly conserved family of EH domain-containing proteins. , 2000, Genomics.

[20]  J. Biggs,et al.  Self-tolerance and the composition of T cell repertoire , 2000, Immunologic research.

[21]  M. Probst-Kepper,et al.  A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription , 1999, The Journal of experimental medicine.

[22]  Anajane G. Smith,et al.  Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. , 1999, Blood.

[23]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[24]  A. Gambotto,et al.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Seliger,et al.  Gene Transfer of the Co‐Stimulatory Molecules B7‐1 and B7‐2 Enhances the Immunogenicity of Human Renal Cell Carcinoma to a Different Extent , 1999, Scandinavian journal of immunology.

[26]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  F. Triebel,et al.  A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. , 1999, Journal of immunology.

[28]  P. Moss,et al.  Tetrameric HLA class I–minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease , 1999, Nature Medicine.

[29]  A. McMichael,et al.  Functions of nonclassical MHC and non-MHC-encoded class I molecules. , 1999, Current opinion in immunology.

[30]  D. Speiser,et al.  Alloreactive cytotoxic T cells recognize minor transplantation antigens presented by major histocompatibility complex class Ib molecules. , 1998, Transplantation.

[31]  D. Goodlett,et al.  HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. , 1998, Journal of immunology.

[32]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[33]  P. Beverley,et al.  In vitro responses of human CD45R0brightRA− and CD45R0−RAbright T cell subsets and their relationship to memory and naive T cells , 1997, European journal of immunology.

[34]  G. Riethmüller,et al.  Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy , 1997, Journal of Molecular Medicine.

[35]  R. Colvin,et al.  Molecular and cellular events implicated in local tolerance to kidney allografts in miniature swine. , 1997, Transplantation.

[36]  P. Dietrich,et al.  In situ demonstration of renal‐cell‐carcinoma‐specific T‐cell clones , 1996, International journal of cancer.

[37]  F. Marincola,et al.  Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. , 1996, Journal of immunology.

[38]  H. V. van Houwelingen,et al.  Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. , 1996, The New England journal of medicine.

[39]  J. Shabanowitz,et al.  Use of tandem mass spectrometry for MHC ligand analysis , 1996 .

[40]  B. Seliger,et al.  Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones , 1994, International journal of cancer.

[41]  E. Sercarz,et al.  The T cell repertoire against cryptic self determinants and its involvement in autoimmunity and cancer. , 1994, Clinical immunology and immunopathology.

[42]  D. Schendel,et al.  HLA class I alleles of LCL 721 and 174 x CEM.T2 (T2). , 1994, Tissue antigens.

[43]  C. Croce,et al.  The human eps15 gene, encoding a tyrosine kinase substrate, is conserved in evolution and maps to 1p31-p32. , 1994, Oncogene.

[44]  G. Riethmüller,et al.  Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. , 1993, Journal of immunology.

[45]  M. Herlyn,et al.  Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients , 1993, The Journal of experimental medicine.

[46]  L. Sherman,et al.  The molecular basis of allorecognition. , 1993, Annual review of immunology.

[47]  A. Bakker,et al.  Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. , 1992, Journal of immunology.

[48]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[49]  A. Belldegrun,et al.  Autologous Tumor-Specific Cytotoxicity of Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell Carcinoma , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[50]  S. Yang,et al.  Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. , 1990, The New England journal of medicine.

[51]  J. Finke,et al.  Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. , 1990, Cancer research.

[52]  P. Parham,et al.  Rapid cloning of HLA-A,B cDNA by using the polymerase chain reaction: frequency and nature of errors produced in amplification. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[53]  G. Ogg,et al.  Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes , 1989, Nature.

[54]  A. McMichael,et al.  Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[55]  A. Belldegrun,et al.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. , 1988, Cancer research.

[56]  J. Miller,et al.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system , 1987, Molecular and cellular biology.

[57]  B. Malissen,et al.  Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. , 2008, Tissue antigens.

[58]  P. Cresswell,et al.  Monoclonal antibody to HLA-A3. , 1982, Hybridoma.

[59]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[60]  P. Parham,et al.  A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. , 1980, Human immunology.

[61]  L. Lampson,et al.  Two populations of Ia-like molecules on a human B cell line. , 1980, Journal of immunology.

[62]  C. Barnstable,et al.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.